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Abstract: 
 
Background:  
 
Alcohol related withdrawal symptoms are common problems encountered in 
alcohol dependent patients. Withdrawal symptoms exist in a continuum and 
there is need for timely treatment of these withdrawal symptoms in order to 
prevent complicated withdrawal states like Delirium tremens and withdrawal 
seizures. The treatment is by administration of benzodiazepines and the 
usual practice is to start patients on an empirical dose, “Fixed schedule 
treatment”. But there is another method called the “Symptom triggered 
treatment” for administering benzodiazepines which utilizes a rating scale 
called the Clinical Institute Withdrawal Assessment Scale (CIWA-Ar), 
which helps in giving medications according to severity of the withdrawal 
rating.  
 
 
 
 
 
[9] 
 
 
 
Aims of the Study:  
 
To compare between the two regimens for alcohol detoxification namely, the 
“Symptom triggered treatment” and the “Fixed schedule treatment” for 
outcome variables: Dose of benzodiazepine, duration of treatment and 
severity of withdrawal. 
 
Methods: 
 
 Prospectively we randomized consenting, consecutive patients, admitted 
with the diagnosis of alcohol dependence syndrome according to DSM-IV 
criteria into either of the 2 detoxification treatment methods: 1)Fixed 
schedule treatment or 2)Symptom triggered treatment. 
 
 
 
 
 
[10] 
 
 
 
Results:  
 
The “Symptom triggered treatment” group required 93 mg lesser mean 
benzodiazepine dose than the “Fixed schedule treatment” group. The mean 
duration of treatment in the “Symptom triggered treatment” was 2.12 days 
lesser than the “Fixed schedule treatment.” There was a group of patients 
who did not require any benzodiazepine during detoxification and they were 
significantly higher in the “Symptom triggered treatment” group (24%) 
when compared with the “Fixed schedule treatment” group (4%). No 
incidences of any complicated withdrawal symptoms during course of 
detoxification in the sample. 
 
Conclusions:  
 
The Symptom triggered treatment using CIWA-Ar scale may be a safe and 
better treatment option for patients during alcohol detoxification in terms of 
lower benzodiazepine dose and shorter duration of treatment. 
 
[11] 
 
 
Introduction: 
 
According to the World Health Organization, there are about 2 billion 
people in this world who are using alcoholic beverages and among them 
76.3 million have diagnosable alcohol related disorders who need treatment.  
 
According to the newly compiled Alcohol Atlas of India, there is an 
alarming increase in alcohol consumption in the country and also the age of 
starting alcohol consumption is decreasing at an alarming rate(1)
 
 
Alcohol withdrawal 
 
Many patients on suddenly stopping or decreasing alcohol intake , would 
experience alcohol related withdrawal symptoms. Alcohol is a CNS 
depressant, so the withdrawal symptoms related to alcohol would be more of 
activation type, like coarse tremors of hands, insomnia, anxiety, increased 
BP, heart rate, body temperature, respiratory rate, nausea, vomiting, 
headache etc(2).  
[12] 
 
 
About 95 % or more of the withdrawal symptoms are of the mild to 
moderate type with above mentioned symptoms. But around 3-5 % of the 
patients may experience a complicated withdrawal state(3). 
 
Some of the complicated withdrawal conditions related to alcohol include 
Delirium Tremens, withdrawal seizures, Alcoholic Hallucinosis. 
Delirium and convulsions carry high morbidity and mortality (4) (5). 
 
The treatment of these alcohol withdrawal symptoms is called 
detoxification. Benzodiazepines are the treatment of choice for 
detoxification (6) and meta-analyses have proved that Benzodiazepines have 
greater efficacy, and good margin of safety (7)(8)(9).  Benzodiazepines that are 
commonly used for detoxification are Chlordiazepoxide, Diazepam or 
Lorazepam
. 
 
 
 
 
 
[13] 
 
 
It has been shown that the Benzodiazepines not only help to improve the 
symptoms related to alcohol withdrawal, but that if started in timely manner, 
it is also helpful in reducing the incidence of complicated withdrawal states 
like Delirium Tremens and withdrawal seizures(7).  
 
Mechanism of action of the Benzodiazepines is similar to the effect of 
alcohol; these medications also enhance the effect of the neurotransmitter 
GABA on the brain. Thus the medication can be initiated and slowly tapered 
and stopped in order to treat the alcohol related withdrawal symptoms. 
 
 
 
 
 
 
 
 
 
 
 
[14] 
 
 
Administration of Benzodiazepines 
 
Regarding the administration of Benzodiazepines for treatment of alcohol 
withdrawal symptoms, the general practice is to administer the medications 
orally and the initial dose is decided empirically and then it is slowly tapered 
and stopped. The decision on the initial dosage of the benzodiazepine is 
decided empirically by taking into consideration the amount of alcohol 
consumption by the patient and the history of withdrawal symptoms and past 
history of any complicated withdrawal symptoms in which case a higher 
dose is started (9).  
 
But some studies have shown that this method sometimes results in using 
large doses of benzodiazepines and whereas some patients also seem to 
undergo safe and comfortable withdrawal period without any 
pharmacological intervention also(10). 
 
 
[15] 
 
 
But in routine practice most patients receive benzodiazepines during their 
withdrawal phase (10).  It is also been shown that under dosing of the 
benzodiazepine medications can lead to complicated withdrawal symptoms 
in the patient like withdrawal seizures and Delirium Tremens(11). 
Thus the determination of the dose of benzodiazepine that has to be started 
for a patient, who comes in alcohol withdrawal phase, is of very high 
significance. For this there exists certain alcohol related withdrawal 
symptom assessment scales with which we can systematically and 
periodically assess the severity of the withdrawal symptoms and which 
provides guidelines for administration and dosing of the benzodiazepines 
accordingly(4) (11) (12)(13).  
One such validated scale is the revised Clinical Institute Withdrawal 
Assessment for Alcohol (CIWA-Ar)(12) (13). 
 
 
 
 
[16] 
 
The CIWA-Ar Rating Scale 
 
The CIWA-Ar rating scale developed by Sullivan et al,  is a validated scale 
that helps to measure the severity of alcohol related withdrawal 
symptoms(14). In addition to that it is also useful in monitoring the clinical 
course of the withdrawal period and also helps to identify patients at risk of 
developing complicated withdrawal symptoms like delirium tremens and 
withdrawal seizures(15)(16)(17). 
 
The scale is clinician administered and has 10 items consisting of 
withdrawal symptoms like nausea/ vomiting, Tremor, Paroxysmal sweats, 
anxiety, agitation, tactile, auditory, visual disturbances, headache and 
Orientation(14). 
 
Each item is scored in graded manner according to increasing severity, from 
0-7, except for Orientation which is scored from 0-4. A total rating score of 
more than 15 is indicative of a higher risk for developing complicated 
withdrawal (RR- 3.72; 95% confidence interval 2.82 –4.85). The higher the 
score, the greater is the risk for complicated withdrawal (18)(19)(20). 
 
[17] 
 
 
Symptom triggered treatment for Alcohol withdrawal 
Studies have shown that the protocol for administering benzodiazepines for 
treatment of alcohol withdrawal can be standardized based on the CIWA-Ar 
rating score (21).  
This is done by administering the CIWA-Ar scale every hour for the patient, 
during which the benzodiazepine is administered whenever the score is 
greater than or equal to 10. The rating is continued every hour till the score 
comes below 10 and after which it is continued every 4th hourly(21).  
Rating is done totally for a period of first 24 hours in this manner and the 
next day onwards the total dose of benzodiazepine received on the first day 
is given in divided doses and then tapered by 10mg daily from the third day 
onwards (21).  
This method of  detoxification is called symptom triggered treatment. This 
is an efficient method for detoxification as it helps in administering the 
benzodiazepines in an efficient manner according to the severity of 
symptoms of the individual patients(22).  
 
[18] 
 
This is more of an individualized approach in treatment of withdrawal 
symptoms and may be a better method for calculating the accurate dosage of 
benzodiazepines to administer for these patients than the treatment as usual, 
in which the dose is empirically decided(23)(24).  
However there are only two randomized controlled studies till now that have 
compared between the symptom triggered approach and fixed schedule 
treatment. Both these studies had reported that the symptom triggered 
approach was better in terms of duration and dosage of benzodiazepine 
administration (23) (24).  
 
 
 
 
 
 
 
 
 
[19] 
 
 
Review of Literature: 
 
In Switzerland,  Daeppen et al (2002) (23)  did a prospective randomized 
double blind placebo controlled trial comparing symptom triggered and 
fixed treatment schedule for managing alcohol withdrawal symptoms.  
 
They recruited 117 alcohol dependent patients diagnosed according to 
Diagnostic Statistical Manual- IV criteria and who had taken last alcohol 
drink within 72 hrs prior to time of admission. Oxazepam was used as the 
detoxifying agent.  
 
In the Fixed Schedule treatment group, on the first day they received 
Oxazepam 30mg tablets, 6th hourly, and then on the second and third days 
they received 15mg,  6th hourly. Also half an hour after taking each tablet, 
CIWA-Ar was administered and if the score was between 8 and 15, they 
received 15mg of oxazepam and if score was above 15 , they received 30mg 
of oxazepam. The CIWA-Ar rating was done every half an hour until the 
score came below 8. 
 
[20] 
 
 
In the symptom triggered treatment group, the patients received placebo in 
the same manner as oxazepam in the fixed schedule regimen. And also the 
patients were monitored with CIWA-Ar every half an hour and 
administered oxazepam accordingly as mentioned above until the CIWA-Ar 
score came below 8. Nursing staff  in charge of administering the CIWA-Ar 
scale and oxazepam were blinded to treatment allocation. 
 
The study revealed a significant reduction in the mean oxazepam dose 
administered in symptom triggered group (37.5mg) compared to the fixed 
schedule group (231.4mg) with a p value < 0.001 . 
 
 
 
 
 
 
 
 
 
[21] 
 
 
In another study, by Saitz et al (1994) (24), which was a prospective 
randomized double blind placebo controlled trial, used Chlordiazepoxide, 
to compare fixed treatment schedule and symptom triggered treatment.  
 
They randomized 101 patients and allocation was done by a pharmacist who 
was blinded to the study protocol. 
 
In the fixed schedule treatment, on the first day, patients received 50mg of 
chlordiazepoxide 6th hourly and on the 2nd and 3rd days they received 25 mg 
6th hourly. In addition they were also monitored with CIWA-Ar rating every 
hour and they received chlordiazepoxide 25-100mg depending on the 
CIWA-Ar score, whenever it went above 8. 
 
 
 
 
 
 
 
[22] 
 
 
In the symptom triggered treatment group, patients received placebo 6th 
hourly for three days. And in addition they were monitored with CIWA-Ar 
scale every hour until the score came below 8.  
 
Patients were administered chlordiazepoxide doses ranging from 25-100mg 
depending on the CIWA-ar scores. Nurses who were blinded to treatment 
allocation decided and administered the chlordiazepoxide according to the 
CIWA-Ar scale. 
 
This study also revealed a significantly lesser amount of chlordiazepoxide 
needed in the symptom triggered group (100mg) as compared with the fixed 
schedule (425mg) with p value <0.001. 
 
 
 
 
 
 
 
[23] 
 
Rationale for our study: 
 
The above 2 western studies (23)(24), while comparing symptom triggered 
therapy with fixed regime treatment, used CIWA-Ar scale even in fixed 
regime treatment arm to give extra benzodiazepine. We believe that this 
would have contaminated the groups.  
 
Hence, we planned to study the two groups but strictly not using CIWA-Ar 
to assist the benzodiazepine administration in fixed regime treatment. In 
fixed regime treatment, the dose of benzodiazepine should be empirically 
decided and fixed at the beginning itself.   
 
In our study we wanted to adopt the method of using CIWA-Ar for 
determining the benzodiazepine dose in the symptom triggered group alone.  
 
 
 
 
 
 
[24] 
 
 
All the published studies using CIWA – Ar were done in the west and on 
searching the literature, we did not find any published research from India. 
Drinking practices vary substantially among different countries and this 
difference should be taken into account and culture specific treatment 
measure should be developed (25).   
 
Hence, we decided to see whether symptom triggered therapy is feasible in 
our culture after giving adequate training to residents and nursing staff.  
 
 
 
 
 
 
 
 
 
 
[25] 
 
 
AIMS: 
 
In patients with alcohol dependence syndrome, during the detoxification 
phase, to assess whether Symptom triggered treatment (STT) would 
differ from Fixed schedule treatment (FST) with respect to : 
 
1) Dose of benzodiazepines needed to manage withdrawal symptoms 
 
2) Duration of detoxification and  
 
3) Complications and severity of withdrawal symptoms. 
 
 
 
 
 
 
 
 
[26] 
 
 
METHODOLOGY: 
 
All the consecutive patients, between the ages of 16 and 65 years, admitted 
to our psychiatry ward with the diagnosis of alcohol dependence syndrome, 
were screened for study inclusion.  
 
After explaining the study protocol, we got written informed consent from 
the patient and the family member who had accompanied the patient. 
Patients who gave voluntary consent would enter the study and patients who 
are not having capacity to give consent because of delirium were included 
only if the family members give valid consent.  
 
Consenting patients were interviewed by the researcher using Structured 
Clinical Interview for DSM IV (SCID)(26) and only patients fulfilling DSM 
IV criteria for alcohol dependence syndrome were included.  
 
 
 
 
[27] 
 
 
In patients who had delirium, if the causes for delirium were found to be 
other than alcohol withdrawal, then they were excluded from the study.  
 
Eligible patients were interviewed to get demographic characteristics, 
medical co-morbidities, smoking status and use of any other substances or 
prescribed drugs during the last 30 days.  
 
We used the Severity of Alcohol Dependence Questionnaire (SADQ) to 
assess the severity of dependency. This is a 20-item, self-rated questionnaire, 
which has been developed to provide a brief and replicable method of 
assessing the severity of alcohol dependence syndrome
 
(27). 
 
 As SADQ is not validated, we have translated the questions from English to 
Tamil and back to English and only the questions which retain the original 
meanings were used in the Tamil version. For other questions, we repeated 
the whole procedure of translations till valid translated Tamil version was 
obtained. We used the Tamil version of SADQ on all patients enrolled into 
the study. 
 
[28] 
 
 
CIWA – Ar was administered to all the patients to get the baseline score. 
 
Then by using computer generated randomization technique, we randomized 
the patients into one of the 2 detoxification regimes: 1) Fixed schedule 
treatment or 2) Symptom triggered treatment. 
  
 
1) Fixed schedule treatment (FST):  
 
For patients randomized to this group, the admitting psychiatrist decides 
about the initial dose of benzodiazepine (Chlordiazepoxide or Lorazepam). 
From day 3, the dose was reduced and in case of Chlordiazepoxide the 
reduction was by 10mg per day and if it was Lorazepam the reduction was 
by 1mg per day.  
 
 
 
 
 
[29] 
 
 
2) Symptom triggered treatment (STT): 
 
The treatment team (nurse staff/resident) on the ward administered CIWA-
Ar immediately after the patient was recruited into the study. If the score 
was above 10, the patient was given 20mg of Chlordiazepoxide.  
 
Thereafter, CIWA-Ar was administered every hour till the score reached 
below 10 and maintained score less than 10 on total of three successive 
readings.
 
After that CIWA – Ar rating scale was administered once in 4 
hours and if any time the score went above 10, the scale administration was 
rescheduled to once an hour again.  
 
 
 
 
 
 
 
 
[30] 
 
 
Any time the score went above 10, the patient received 20mg of 
Chlordiazepoxide orally. The total amount of Chlordiazepoxide that the 
patient got on Day 1 was given on the second day as divided doses. From 
day 3, the dose of Chlordiazepoxide was tapered by 10mg every day. 
 
 For patients where Chlordiazepoxide was contraindicated for medical 
reasons like hepatic dysfunction, we used equivalent dose of Lorazepam i.e. 
1mg each time the score was 10 or above, and tapered the daily dosing by 
1mg daily from the third day onwards. 
 
This method of benzodiazepine administration had been validated earlier (6).  
 
From the second day onwards CIWA – Ar was administered for both the 
groups, every morning between 8 am and 10 am, by an investigator who was 
blind to the treatment allocation for a period of 7 days.  
 
 
 
 
[31] 
 
 
Training nursing staff and residents: 
 
Before starting this study, we trained the nursing and residents in 
administering CIWA – Ar scale among patients with varying severity of 
alcohol withdrawal state. At the end of the training, we found that the single 
measure intra class correlation co-efficient was 0.898 indicating a high level 
of agreement for all the items of CIWA – Ar (28).
 
 
 
 
 
 
 
 
 
 
 
 
[32] 
 
 
Sample Size Determination 
 
We sampled 25 patients who were admitted for alcohol dependence 
syndrome in our psychiatry ward. In this group, the mean dose of 
chlordiazepoxide administered was 139.6 mg (standard Deviation 70.44) and 
this was by the fixed schedule method.  
 
We hypothesized that in our prospective study, by following symptom 
triggered method, if the mean dose of chlordiazepoxide could be reduced by 
at least 50mg, we would consider that as a clinically significant difference.  
 
By using the above figures and keeping α at 0.05 and power of the study at 
90, we estimated the sample size with the formula: 
 
2 x  [SD x ( Zα + Zβ) / Mean difference ]2 , 
(SD = 70.444, Zα = 1.96 , Zβ = 0.84, and Mean difference = 50 mg). 
 
By this calculation, we found that we needed 31 patients in each group. 
 
[33] 
 
 
Outcome measures: 
 
Primary outcomes: 
 
1. Amount of benzodiazepines in both the groups; we would measure the 
mean dose of benzodiazepines administered.  
 
2. The duration of detoxification period: The mean time duration of 
benzodiazepine administration. 
 
3. CIWA – Ar ratings in both the treatment groups.  
 
Secondary outcomes: 
 
1. Withdrawal complications like, delirium tremens and rum fits. 
 
 
 
[34] 
 
 
Statistical Analysis 
 
We performed statistical analysis with PASW (SPSS) version 18.0 for 
Windows. 
 
We compared the Fixed schedule treatment group and the symptom 
triggered group in the following variables: Age, Marital status, socio 
economic status, SCID criteria, SADQ scores, smoking status, co morbid 
medical illness, CIWA-Ar scores, Benzodiazepine doses, duration of 
detoxification phase and complicated withdrawal. 
 
We used descriptive statistics to get the mean and standard deviation of 
continuous variables. Student t test was used to compare continuous 
variables like age, socioeconomic status, SADQ total scores, CIWA-Ar 
baseline scores, total equivalent benzodiazepine doses and number of 
detoxification days. 
 
 
 
[35] 
 
 
We used chi-square test to compare dichotomous variables like marital 
status, smoking status, other substance use status, co morbid medical illness 
status, SCID criteria, dichotomized CIWA-Ar score with cut off as10, 
complicated withdrawal, and patients who needed no benzodiazepine.  
 
We used Mann Whitney test (non Parametric test) to compare variables like 
daily mean benzodiazepine doses and daily CIWA-Ar scores between the 
Fixed schedule treatment group and the Symptom triggered group. We used 
Mann Whitney test also to compare total benzodiazepine equivalent dose 
between the delirium and non delirium groups. 
 
 
 
 
 
 
 
 
[36] 
 
 
Results: 
 
A total of 50 patients who fulfilled the inclusion criteria were randomly 
assigned to either the “Fixed schedule treatment” (FST) or the “Symptom 
triggered treatment” (STT) groups. Thus there were 25 patients in each of 
these groups. 
 
Dropouts: 
There were a total of 4 dropouts in the study. One dropout was from the 
“Fixed schedule treatment” group who dropped out on the 6th day and 
remaining three dropouts were from the “symptom triggered treatment” 
group, who dropped out on the 4th day. The reasons for dropout for all these 
patients were discharge from hospital before completing detoxification. 
Their data till their drop were used for analysis. (Fig 1) 
 
 
 
 
 
[37] 
 
 
 
Fig 1:Flow chart for study recruitment and characteristics of study groups 
 
 
[38] 
 
 
Socio demographic details: 
 
All the patients were of male gender and the mean age of the patients in the 
whole sample was 38.3 yrs (SD- 9.2). There was no statistically significant 
difference between the mean ages in the Fixed schedule treatment group 
(37.8) and the Symptom triggered group (38.9). (Table 1) 
 
 
Table 1 :Age characteristics in the sample; (STT- symptom triggered 
treatment) 
Group 
 
 
No. of Pts 
 
Mean Age 
 
Std. Deviation 
 
FST 25 37.80 9.721 
STT 25 38.92 8.976 
Total 50 38.36 9.277 
 
 
 
[39] 
 
 
Regarding marital status, there were 20 (80%) patients in the Fixed schedule 
treatment group and 18 (72%) patients in the symptom triggered group who 
were married and the rest were either single, separated or divorced.(Table 
2). There was no statistically significant difference between the two groups 
regarding marital status. 
 
 
Table 2 : Marital Status in the sample 
Group 
Marital Status 
Married 
No. (%) 
Single 
No. (%) 
Separated 
No. (%) 
Divorced 
No. (%) 
FST 20 3 2 0 
(80) (12) (8) (0) 
STT 18 3 3 1 
(72) (12) (12) (4) 
Total 38 6 5 1 
(76) (12) (10) (2) 
 
 
 
 
 
[40] 
 
 
Out of the total sample, 3 patients were unemployed and for the rest of the 
47 patients, the mean monthly salary was Rs. 13,019 (SD- 9337.8). There 
was no statistically significant difference regarding the socio-economic 
status between both the groups. 
 
 
Relevant clinical variables of the study population: 
 
The no. of smokers were higher (80%) in the Fixed schedule treatment 
group and this was statistically significant (p value = 0.03) (Table 3).  
 
Whereas the rate of “other substance use” (like chewing betel nut, tobacco 
etc.) was higher in the Symptom triggered treatment group (40%) than in the 
treatment as usual group(24%), but this difference was not statistically 
significant(Table 4).  
 
There was no statistical significance regarding the presence of medical 
illness between the Fixed schedule treatment and the symptom triggered 
treatment groups (Table 5). 
[41] 
 
 
Table 3: No. of smokers in each group 
Group * 
Smoking 
No. of Pts (%) 
yes no 
 FST  
(25) 
 20 5 
 80.0% 20.0% 
STT 
(25) 
 13 12 
 52.0% 48.0% 
Total 
(50) 
 33 17 
 66.0% 34.0% 
*Chi-Square = 4.367, df =1, p=0.037 
 
 
 
 
Table 4: No. of other substance users in both the groups 
Group Other subs use 
No. of Pts (%) 
yes no 
 FST  
(25) 
 6 19 
 24.0% 76.0% 
STT 
(25) 
 10 15 
 40.0% 60.0% 
Total 
(50) 
 16 34 
 32.0% 68.0% 
[42] 
 
 
 
 
Table 5: Co morbid Medical illness in both the groups 
 
 
 
 
 
 
 
 
 
Group 
Medical Illness 
No. of Pts (%) 
 
yes No 
 FST  
(25) 
 9 
36.0% 
16 
64.0% 
   
STT 
(25) 
 
 8 17 
 32.0% 68.0% 
Total 
(50) 
 17 
34.0% 
33 
66.0% 
   
[43] 
 
 
Profile of Alcohol dependence in the sample: 
 
All the patients fulfilled at least 5 out of  the 7 items in the DSM IV-TR 
criteria for alcohol dependence syndrome. Majority of the patients fulfilled 6 
or 7 of the DSM IV-TR criteria (Table 6). There was no statistically 
significant difference between the fulfillment of SCID criteria between the 
“treatment as usual” and “symptom triggered groups”. 
 
 
Table 6: SCID Criteria in both the groups 
Group 
No. of Criteria fulfilled in  SCID 
 
No. of pts (%) 
5 6 7 
 
 
 
FST  
(25) 
 
0 (0) 
 
12 (48) 
 
13 (52) 
   
 
 
 
STT 
(25) 
 
1 (4) 
 
 
13 (52) 
 
11 (44) 
   
 
Total 
(50) 
 
1 (2) 
 
25 (50) 
 
24 (48) 
   
[44] 
 
 
 
The severity of alcohol dependence measured by the SADQ scale was 
analyzed for both the groups (Table 7).  
 
The mean SADQ score for the sample as a whole was 31.1(SD- 9.5), which 
classifies for severe alcohol dependence (the cut off being 31 and higher on 
SADQ score).  
 
When comparing the mean SADQ scores between the “Fixed schedule 
treatment” and “symptom triggered treatment”, they were equal in severity 
in both the groups and there was no statistically significant difference 
between the two groups ( p value = 0.7).  
 
 
 
 
 
 
 
[45] 
 
 
Table 7: Mean SADQ (total) scores in each group 
Group 
 Mean SADQ Total 
Std. Deviation 
 
 
FST  
(25) 
 
 
31.52 
 
9.980 
 
  
STT 
(25) 
30.76 9.329 
 
  
Total 
(50) 
31.14 9.568 
 
 
 
 
 
 
 
 
 
[46] 
 
 
The mean baseline CIWA-Ar score in the sample as a whole was 9.2 (SD- 7) 
(Table 8). There was no statistically significant difference between the mean 
baseline CIWA-Ar scores in both the groups (p value = 0.6).  
 
The number of patients who had baseline CIWA-Ar score of above 10 in the 
Fixed schedule treatment group  were 9 (36%), and those  in the symptom 
triggered treatment group were 13(52%) . But this difference was not 
statistically significant(Table 9). 
 
 
Table 8: Mean baseline CIWA-Ar scores in both the groups 
Group 
 
Mean 
CIWA-Ar 
Baseline 
Std. Deviation 
 
 
FST  
(25) 
 
 
8.72 
 
7.738 
 
  
STT 
(25) 
9.72 6.426 
 
  
Total 
(50) 
9.22 7.057 
[47] 
 
 
Table 9 : No. of patients according to baseline CIWA-ar scores with cut off 
as 10 in both the groups. 
 
Group 
Ciwa-Ar baseline 
 
<10 
 
No. of Pts ( %) 
>10 
 
No. of Pts ( %) 
 FST  
(25) 
 
16 9 
 
(64.0%) (36.0%) 
STT 
(25) 
 
12 13 
 
(48.0%) (52.0%) 
Total 
(50) 
 
28 22 
 
(56.0%) (44.0%) 
 
Hence, at baseline, the severities of alcohol dependence syndrome and 
withdrawal symptoms are equal in both the “Fixed schedule treatment” 
group and “Symptom triggered treatment” 
 
 
 
 
 
 
 
  
Delirium tremens: 
 
Four patients had delirium tremens; 2 in “
“Symptom triggered treatment”.
 
 
Fig 2: No. of Delirium and non delirium patients in the treatment groups
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Benzodiazepene dosage: 
 
Only 2 patients in our study sample received lorazepam (1in each of the 
treatment groups); hence we converted the dose of lorazepam into 
chlordiazepoxide equivalents. (1mg of lorazepam= 20mg of 
chlordiazepoxide)  
 
In the whole sample, the mean total benzodiazepine dosage was 
significantly higher among the delirium tremens patients as compared to that 
in the non delirium (uncomplicated withdrawal) patients (Table 10), which 
resulted in skewing of the data distribution (Fig 3). Therefore they were 
analyzed separately.  
 
 
 
 
 
 
 
[50] 
 
 
Table 10: Comparison of mean total BZD equivalent dose in delirium and 
non delirium patients. 
 
 
Group
 * 
 
 
 
No. of 
Patients 
 
 
Mean Total 
BZD Eq. 
Dose 
 
Std. Deviation 
 
 
 
 
 
Non Delirium 
 
46 147.39 106.592 
 
 
   
Delirium 
 
4 765.00 132.791 
*Chi-Square= 3.323, df=1, p value = 0.001. 
 
 
 
 
 
 
 
 
 
[51] 
 
 
Fig 3 : Total Benzodiazepine equivalent doses in the delirium and non-
delirium group of patients. 
 
 
 
 
 
 
 
 
[52] 
 
 
In the non- delirium patients, the mean total benzodiazepine equivalent dose 
was significantly lower in the symptom triggered group (100.8mg of 
chlordiazepoxide ), with p value of 0.002. (Table 11). 
 
 
Table 11: Mean total Benzodiazepine dose in both the groups among non 
delirium patients.  
 
 
Group 
 
 
 
 
 
No. of 
non 
delirium 
patients 
 
Mean Total Benzodiazepine  
dose 
(mg) 
Std. Deviation 
 
 
 
 
 
FST 23 193.91 90.541 
 
 
   
 
STT 
 
23 
 
 
100.87 
 
 
102.554 
 
 
 
   
 Total 
 
46 
 
147.39 
 
106.59 
 
*t(44)=3.261, p=0.002 
 
 
 
[53] 
 
 
There were 4 patients with delirium tremens, but there was no statistically 
significant difference in the mean total benzodiazepine doses between the 
“Fixed schedule treatment” and “symptom triggered treatment ” (Table 12). 
 
 
Table 12: Mean total BZD Equivalent dose in both the groups among the 
delirium patients. 
 
 
 
 
 
Group 
 
 
 
 
No. of  
delirium pts 
 
 
 
Mean Total 
Benzodiazepine  dose 
(mg) 
 
 
Std. Deviation 
 
 
 
 
 
 
FST 2 675.00 77.782 
 
 
 
STT 
 
 
2 855.00 120.208 
[54] 
 
 
When comparing daily mean benzodiazepine dosages between the two 
groups, from day 1 to day 7, the symptom triggered treatment group had 
consistently lower mean doses in all the days. The difference was also 
statistically significant in all the days except in day 7 (Table 13, Fig 4). 
 
 
Table 13: Comparison of Total mean daily BZD doses in both the groups. 
Day Total 
Mean Dose 
(mg) 
Mean 
Total Dose 
in  
FST  
(mg) 
 
Mean 
Total Dose 
in  
STT 
  
(mg) 
Chi square 
value 
(df =1) 
p value 
1 49.2 59.2 39.2 3.890 0.000 * 
2 44.8 53.6 36.1 3.245 0.001 * 
3 36.2 43.6 28.8 3.216 0.001 * 
4 27.5 34 20.8 3.118 0.002 * 
5 20.8 25.6 15.9 2.951 0.003 * 
6 13.7 16.6 10.5 2.171 0.03 * 
7 8.5 9.5 7.3 1.190 0.23 
* p value significant ( < 0.05) 
[55] 
 
 
 
Fig 4: Daily mean total BZD doses in each of the treatment groups(symptom 
triggered treatment and Fixed schedule treatment) 
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“Zero”  benzodiazepines: 
 
There were totally 7 patients who did not receive benzodiazepine at all in the 
sample. The number of patients who did not require benzodiazepines was 
significantly higher in the “symptom triggered treatment” group than in the 
“Fixed schedule treatment” group (P value = 0.049) (Table 14).   
 
 
Table 14: Comparison of patients who didn’t receive benzodiazepines 
 
 
 
 
  No. of Pts (%) 
 Group  
No Benzodiazepine 
administered 
Benzodiazepine 
administered 
 
FST  
(25) 
 
 
1 24 
 (4.0%) (96.0%) 
STT 
(25) 
 6 19 
 (24.0%) (76.0%) 
Total 
(50) 
 7 43 
 (14.0%) (86.0%) 
[57] 
 
 
CIWA-Ar daily scores : 
 
There was no statistically significant difference in the daily progression of 
the withdrawal symptom severity when comparing the daily CIWA-Ar 
scores between the Fixed schedule treatment and the symptom triggered 
groups.(Table 15) 
 
 
 
 
 
 
 
 
 
 
 
 
 
[58] 
 
 
Table 15: Comparison of daily CIWA-Ar scores between the treatment as usual and 
symptom triggered groups. 
 
 
CIWA-Ar Scores 
 
Group Day 1  Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
FST  
 
N 
 
25 25 25 25 24 23 23 
Mean 
 
8.72 7.20 3.80 2.32 1.38 1.52 1.65 
(SD) 
 
(7.738) (7.588) (6.671) (3.805) (2.300) (2.333) (2.979) 
STT N 
 
25 25 25 25 22 22 22 
Mean 
 
9.72 4.24 3.16 3.20 1.95 1.77 1.45 
(SD) 
 
(6.426) (3.992) (4.365) (4.282) (3.885) (3.054) (2.521) 
Total N 
 
50 50 50 50 46 45 45 
Mean 
 
9.22 5.72 3.48 2.76 1.65 1.64 1.56 
(SD) 
 
(7.057) (6.184) (5.589) (4.033) (3.136) (2.681) (2.735) 
*No statistically significant difference in the scores. 
 
 
 
 
[59] 
 
 
Duration of Detoxification: 
 
When comparing the number of days of detoxification between the Fixed 
schedule treatment group and the Symptom triggered treatment group, the 
mean number of days for detoxification was significantly lower in the 
symptom triggered treatment group (p value = 0.005). (Table 16).  
 
 
Table 16: Comparison of the mean no. of Detoxification days between the 
treatment as usual and symptom triggered groups. 
 
 
Group * 
 
Mean 
Detoxification Days 
Median Std. Deviation 
 
FST 
 
6.12 6 1.740 
 
   
STT 4.00 5 3.122 
Total 5.06 5 2.721 
*t(48)=2.965, p=0.005 
 
 
 
 
[60] 
 
Discussion: 
 
This prospective randomized controlled study proved our hypotheses that, 
Symptom triggered treatment using CIWA-Ar scale for alcohol 
withdrawal would reduce the dose of benzodiazepine needed and also 
shorten the detoxification duration. 
 
We had recruited a homogenous patient population who qualified for 
Alcohol dependence syndrome according to SCID and who had severe 
dependency as rated by SADQ.  
 
As in the routine clinical practice, all the patients were male with mean age 
of 38 years. Both the ‘Fixed Schedule Treatment’ group and ‘Symptom 
triggered treatment’ group were comparable with respect to 
sociodemograhic factors and more importantly in the severity of 
dependency.  
 
 
 
 
[61] 
 
 
The mean SADQ score was 31.1 (SD- 9.5), which indicates that the 
addiction to alcohol was at a severe level (27). There was no difference in the 
severity of addiction as measured by SADQ and the severity of withdrawal 
symptoms as measured by CIWA-Ar scale at baseline between the “Fixed 
schedule treatment” and “Symptom triggered treatment” groups. 
Randomization would have minimized other confounding variables. 
 
The Symptom triggered treatment group required 93mg (mean) lesser 
chlordiazepoxide dose than the Fixed schedule treatment group. This 
difference in the requirement of benzodiazepine dose was clinically and 
statistically significant from the day1 and it persisted till the end of the 
study.  
 
Another interesting finding, which is also statistically significant, is that 
24% of patients in ‘Symptom triggered treatment’ group and 4% in 
‘Fixed schedule treatment’ group didn’t require any benzodiazepine. 
Also, the symptom triggered treatment group took 2.12 days (mean) 
lesser to complete the detoxification process.   
 
[62] 
 
 
CIWA –Ar ratings was done every day morning by an independent assessor 
who was not part of the investigative team. The mean score of CIWA-Ar for 
both groups was similar on all days, which informs that the effectiveness of 
controlling the withdrawal symptoms was equal in both the treatment arms. 
 
The 4 patients who had delirium tremens had delirium from the beginning of 
their recruitment and none of the patients developed any complicated 
withdrawal symptoms (delirium tremens, seizures, hallucinations) during the 
study period. All the 4 patients recovered from delirium tremens at the end 
of the study.  
 
Sixty six (66%) of the study population were smokers and this was more 
represented in the in the fixed schedule treatment group (80%) than in the 
symptom triggered treatment group (52%), but this might not have affect our 
main results as we are looking only for alcohol related withdrawal 
symptoms. 
 
 
 
[63] 
 
 
Our results are comparable with the western studies which also showed that 
the symptom triggered treatment required less doses of benzodiazepine. In a 
randomized double blind controlled study, the symptom-triggered group 
received 100 mg of chlordiazepoxide, and the fixed dose schedule group 
received 425 mg (24). Surprisingly, as the western study, our symptom 
triggered treatment group also got almost the same mean chlordiazepoxide 
dose: 100.87mg.  
 
However, the mean dose in our   fixed dose schedule group was 193.91mg, 
which was much smaller. This difference could be due to differences in the 
method of administration of fixed dose regimen; in the earlier study, they 
have a fixed starting of chlordiazepoxide as 200mg and in addition subjects 
received extra chlordiazepoxide whenever the CIWA-Ar score went above 8 
(24). 
 
 
 
 
 
[64] 
 
 
In our study, the mean duration of detoxification was significantly lower in 
the symptom triggered treatment group (4 days) when compared with fixed 
schedule treatment group (6.12 days). Similar significant difference was 
seen in earlier studies also. Both Daeppen et al (2002) and Saitz et al (1994) 
adopted a rapid detoxification procedure; benzodiazepines were tapered and 
stopped within 3 days. Still they showed that symptom triggered treatment 
took lesser hours than fixed schedule treatment to complete the 
detoxification (23)(24).   
 
In a larger RCT placebo controlled study done in Switzerland, authors found 
that a total of 61% of patients in symptom triggered group did not require 
benzodiazepine at all (23).  
 
 
 
 
 
 
 
[65] 
 
 
Another research done on 203 problem drinkers admitted to a general 
hospital found that 46% did not experience any significant withdrawal 
symptoms that require any form of pharmacological interventions
 (29).  In our 
study a total of 28% did not require benzodiazepine to manage their 
withdrawal symptoms (24% in the symptom triggered group and 4% in the 
fixed schedule treatment group).  
 
This estimate is lower than the earlier studies and this could be because our 
patient group had qualified for alcohol dependence with higher severity of 
addiction needing admission in a Psychiatric setting. However, our study 
also has confirmed the earlier conclusions that a group of patients do not 
require benzodiazepine during the withdrawal phase.  
 
Fixed predetermined dose of benzodiazepine regimes may subject many 
patients to unnecessary medication, overdoses and excessive sedation. This 
also may prolong the detoxification phase, hospitalization period and 
increase the cost. Literature on alcohol research argues for non 
pharmacologic interventions in acute withdrawal (10)(11). 
 
[66] 
 
 
CIWA-Ar scale in routine practice: 
 
CIWA-Ar is simple to learn and administer and we have successfully trained 
nursing staff and residents in using this(28) . 
 
Despite of research support, even in the west, symptom-triggered regimens 
are not used widely; fixed-schedule chlordiazepoxide constituted the most 
commonly prescribed medication regimen for the treatment of alcohol 
withdrawal (24). 
 
Most of trials with CIWA-Ar  were done in detoxification settings; however 
we could find 2 studies done in general hospital settings which also proved 
that CIWA-Ar  protocol helped in safe and effective detoxification (30)(31). A 
Physician could advice nurses to assess patients using CIWA-Ar at regular 
intervals on the first day of hospital admission. This can be done on patients 
whom the physician suspect having alcohol problems and likely to develop 
withdrawal symptoms. 
 
 
[67] 
 
 
Limitations: 
 
1. As our study is not a double blind study there is a possibility of 
investigator bias. By carefully adhering to the study protocol, we tried 
to overcome this bias. In the ‘fixed schedule treatment’ group, the 
doses of benzodiazepines were decided by the primary treating 
psychiatrists who were not part of the investigative team and they 
were unaware of our hypotheses. In ‘Symptom triggered treatment” 
group, the dose of benzodiazepine was decided by the structured 
administration of CIWA –Ar scale. To further reduce the bias, the 
daily morning rating of CIWA –Ar was done by an independent 
assessor, who was unaware of the treatment allocation. 
 
2. Complicated withdrawal symptoms like delirium tremens, withdrawal 
seizures and alcoholic hallucinosis were poorly represented in our 
sample. However no complicated withdrawal symptoms occurred 
after recruitment suggests that symptom triggered treatment 
effectively prevented them.  
 
[68] 
 
 
3. The study setting happened in psychiatry ward where we have 
psychiatry residents and nursing staff with psychiatry skills. Hence, 
we are not sure whether same outcome could be expected in other 
medical settings. 
 
 
4. We were not able to achieve the target sample size of 62 patients 
owing to time constraints. But with the current sample size itself we 
were able to obtain statistical and clinical significance in the outcome 
variables between the two treatment regimens. 
 
 
 
 
 
 
 
 
 
 
[69] 
 
 
CONCLUSION 
 
 
As per our results we are able to see that there was a significant decrease in 
the dosage of benzodiazepines that was required for detoxification when 
using the symptom triggered method as against the fixed schedule treatment. 
Thus symptom triggered approach would be helpful in preventing excess of 
sedation that occurs in some patients when the benzodiazepine dose is more 
than what is actually needed. 
 
 Also our results show that there were a group of patients who did not 
require any benzodiazepine in the symptom triggered regimen, who would 
have been otherwise started on benzodiazepines if they were on fixed 
regimen treatment.  
 
 
 
 
 
[70] 
 
 
There was also no significant difference in the withdrawal severity in all the 
days throughout the detoxification period between both the treatment 
groups. And there were no incidents of any complicated withdrawal 
symptoms during the course of detoxification, indicating that symptom 
triggered regimen can be considered as a safe alternative for detoxification.  
 
Our results also shows a significant shorter duration of detoxification period 
itself in the patients on symptom triggered regimen compared to fixed 
schedule treatment group. This could mean shorter duration of hospital stay 
and cutting costs for the patient and probably better patient satisfaction. At 
the background of a difficult withdrawal phase, the patients could perceive 
the care to be more satisfying, if they are monitored regularly with CIWA-
Ar  as in the symptom triggered treatment.  
 
Symptom triggered treatment seems to be a favorable, safe and effective 
method of detoxification for alcohol related withdrawal symptoms in 
patients admitted in an In-patient hospital set up with nursing staff or 
residents who are trained in using the CIWA-Ar to administer the 
benzodiazepines. 
[71] 
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APPENDIX 2 
DSM-IV-TR Alcohol Dependence criteria- Diagnostic Code 
303.90 
A maladaptive pattern of alcohol use, leading to clinically significant 
impairment or distress, as manifested by three (or more) of the following, 
occurring at any time in the same 12-month period: 
(1) tolerance, as defined by either of the following: 
(a) a need for markedly increased amounts of alcohol to achieve Intoxication 
or desired effect 
(b) markedly diminished effect with continued use of the same amount of 
alcohol 
(2) Withdrawal, as manifested by either of the following: 
(a) the characteristic withdrawal syndrome for alcohol  
(b) alcohol (or a closely related drug such as valium) is used to relieve or 
avoid withdrawal symptoms. 
 
[84] 
 
(3) alcohol is often used in larger amounts or over a longer period than was 
intended 
(4) there is a persistent desire or unsuccessful efforts to cut down or control 
alcohol use 
(5) a great deal of time is spent in activities necessary to obtain alcohol, use 
alcohol, or recover from its effects 
(6) important social, occupational, or recreational activities are given up or 
reduced because of alcohol use 
(7) alcohol use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been 
caused or exacerbated by alcohol (e.g. continued drinking despite 
recognition that an ulcer was made worse by alcohol consumption) 
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APPENDIX 3 
 
SEVERITY OF ALCOHOL DEPENDENCE QUESTIONAIRE (SADQ-C)1 
 
Please recall a typical period of heavy drinking in the last 6 months. 
When was this? Month:………………………………. Year…………………………….. 
Please answer all the following questions about your drinking by circling your most 
appropriate response. 
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APPENDIX 4  
 
SEVERITY OF ALCOHOL DEPENDENCE  QUESTIONNAIRE 
(Tamil translated version) 
 
 
[88] 
 
 
 
 
 
 
[89] 
 
 
 
 
 
 
 
 
[90] 
 
APPENDIX 5  
Clinical Institiute withdrawal assessment for Alcohol scale - revised 
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APPENDIX 6:  
 
Clinical Instititute Withdrawal Assessment for Alcohol Scale (CIWA-
Ar) –Tamil transalted version  
 
 
[93] 
 
 
 
 
[94] 
 
 
 
 
[95] 
 
 
 
 
[96] 
 
APPENDIX 7 
DATA COLLECTION PROFORMA 
 
1. Name: 
 
2. Age: 
 
3. Sex: 
 
4. I.P No. 
 
5. Marital Status: Married/ Unmarried/separated/divorced 
 
6. Socio-Economic Status:(average monthly income) 
 
7. Smoking:  
 
Yes/No. If Yes, then Specify No. of cigarettes /beedies per day 
:______ 
 
 
8. Other Substance use:  
 
Yes/No. If Yes, then Specify ______ 
 
 
9. Medical Illness: 
 
 
 
 
10. SCID INTEVIEW SCHEDULE FOR ALCOHOL 
DEPENDENCE SYNDROME 
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11. SADQ :  
 
 Questionairre 
 
 Total Score: 
 Impression: 
 
 
 
12. CIWA-Ar Score: 
 
 
Ciwa-Ar 
 
Chlordiazepoxide 
(C)/ 
Lorazepam (L) 
Total dose of 
BZD  
Day 1 (Baseline) 
   
Day 2 
   
Day 3 
   
Day 4 
   
Day 5 
   
Day 6 
   
Day 7 
 
  
 
Total Dose of Chlordizapoxide / Lorazepam received : _____mg 
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13. 
 
Withdrawal 
Complications 
 
Day 1  
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
 
 
 
 
14. CSQ Score 
 
 
CSQ Score 
 
Day 2 
 
Day 3 
 
Day 4 
 
Day 5 
 
Day 6 
 
Day 7 
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APPENDIX 8 
CIWA- Ar scoring sheet 
 6  
am 
7 
am 
8 
am 
9 
Am 
10 
am 
11 
Am 
12 
noon 
1 
pm 
2 
pm 
3 
pm 
4 
pm 
5 
pm 
Nausea and 
vomitting 
            
Tremor             
Paroxysmal 
sweats 
            
Anxiety             
Agitation             
Tactile 
disturbances 
            
Auditory 
disturbances 
            
Visual 
disturbances 
            
Headache, fullness 
in head 
            
Orientation and 
clouding of 
sensorium 
            
 
 
Total score 
 
 
            
Benzodiazepine * 
dose( if total 
score >10) 
 
 
            
* Write as ‘L 1mg’ for lorazepam and ‘C20mg’ for Chlordiazepoxide 
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 6  
pm 
7 
pm 
8 
pm 
9 
pm 
10 
pm 
11 
Pm 
12 
Mid 
night 
1 
am 
2 
am 
3 
am 
4 
am 
5 
am 
Nausea and 
vomitting 
            
Tremor             
Paroxysmal 
sweats 
            
Anxiety             
Agitation             
Tactile 
disturbances 
            
Auditory 
disturbances 
            
Visual 
disturbances 
            
Headache, fullness 
in head 
            
Orientation and 
clouding of 
sensorium 
            
 
 
Total score 
 
 
            
Benzodiazepine * 
dose( if total 
score >10) 
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APPENDIX 9 
 
Informed Consent – English Version 
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR STUDENT RESEARCH 
PROJECTS 
 
I   
 
Post Graduate (M.D Psychiatry), Year 2010, Regular Batch  student of the 
PSG Institute of Medical Sciences & Research (PSG IMS&R), am carrying 
out a study on the topic: Symptom – Triggered Therapy for Alcohol 
Withdrawal by using Revised Clinical Institute Withdrawal Assessment of  
Alcohol Scale (CIWA-Ar) by nursing staff – a Randomised Control Study as 
part of my student research project being carried out under the aegis of the 
Department of Psychiatry  
 
Our research guide is Prof. Raghuthaman     
 ; Designation: Head of Department 
 
The justification for this study is:  
 
To compare between the symptom triggered regimen and fixed schedule 
regimens for treatment of alcohol related withdrawal symptoms.  . 
 
The aims of this study are:  
 
Primary Aim: To calculate mean dose of Librium administered and duration 
of treatment in both fixed schedule group and symptom triggered group 
 
Secondary Aims: Occurrence of any withdrawal complications like delirium 
tremens and rum fits. 
 
 
Sample size: 50.   Respondents are All the consecutive patients, between 
the ages of 16 and 65 years, admitted to our psychiatry ward with the 
[102] 
 
diagnosis of alcohol dependence syndrome. Location: PSGIMSR, 
Coimbatore.  
 
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We 
will be carrying out Initial interview: 30 minutes.  
 
 
Medication given would be chlordiazepoxide or lorazepam during the 
detoxification period either according to symptom triggered or the fixed 
schedule regimen.  
 
Final interview : 30 mts.  
 
 
Benefits from this study, if any: Lesser duration of stay in hospital and 
prevention of major withdrawal symptoms like  delirium tremens. 
 
How the results will be used: For adopting better regimens for treatment of 
alcohol related withdrawal symptoms.  
 
 
If you are uncomfortable in answering any of our questions during the 
course of the interview / biological sample collection, you have the right to 
withdraw from the interview / study at anytime. You have the freedom to 
withdraw from the study at any point of time. Kindly be assured that your 
refusal to participate or withdrawal at any stage, if you so decide, will not 
result in any form of compromise or discrimination in the services offered. 
You will continue to have access to the regular services offered to a patient. 
You will NOT be paid any remuneration for the time you spend with us for 
this interview / study. The information provided by you will be kept in strict 
confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall 
be used for approved research purposes only.  
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Consent: The above information regarding the study, has been read by me/ 
read to me, and has been explained to me by the student investigators from 
the PSG IMS&R. Having understood the same, I hereby give my consent to 
them to interview me. I affixing my signature / left thumb impression to 
indicate my consent and willingness to cooperate in this study.  
 
 
Respondent ID: _________.    
Signature / Left thumb impression of the Respondent.   
 
 
 
Signature of the Interviewer with date 
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APPENDIX 10 
 
Informed Consent form- Tamil Version 
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